Company Encyclopedia
View More
name
Monte Rosa Therapeutics
GLUE.US
Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body’s natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops orally bioavailable molecular glue degraders (MGDs), such as MRT-2359 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of neurologic and systemic autoimmune and inflammatory diseases; and MRT-8102 for the treatment of inflammatory diseases driven by IL-1b and the NLRP3 inflammasome. In addition, it develops CDK2 to treat multiple cancers, including ovarian, endometrial, gastric and breast. Further, its pipeline includes programs in immunology and inflammation indications, oncology, cardiovascular, metabolic, and genetic diseases.
1.902 T
GLUE.USMarket value -Rank by Market Cap -/-

Financial Score

14/12/2025 Update
B
BiotechnologyIndustry
Industry Ranking32/393
Industry medianC
Industry averageD
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreC
    • ROE9.28%B
    • Profit Margin11.54%B
    • Gross Margin-171.38%E
  • Growth ScoreA
    • Revenue YoY1112.27%A
    • Net Profit YoY117.54%A
    • Total Assets YoY45.94%A
    • Net Assets YoY19.65%A
  • Cash ScoreA
    • Cash Flow Margin866.70%B
    • OCF YoY1112.27%A
  • Operating ScoreC
    • Turnover0.47C
  • Debt ScoreC
    • Gearing Ratio46.54%C

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Dr. Jun O. Liu, founder of Rapafusyn, named National Academy of Inventors Fellow for contributions to molecular glue field.

    Dr. Liu has been awarded a prestigious honor for his groundbreaking work in the molecular glue field, which has significantly impacted scientific innovation, translational science, and human health. The recognition was announced in Baltimore on December 11, 2025. Dr. Liu's contributions have shaped the field, with his research having important implications for various areas. His work has played a crucial role in advancing knowledge in this domain, leading to new discoveries that hold promise for improving human health.

    Unusual Whales·
    US
    GLUE
    -1.51%
    Unusual Whales·
    US
    GLUE
    -1.51%

    Piper Sandler Reaffirms Their Buy Rating on Monte Rosa Therapeutics (GLUE)

    Piper Sandler analyst Edward Tenthoff reiterated a Buy rating for Monte Rosa Therapeutics, setting a price target of $20. The analyst has an average return of -8.8% and a 33.95% success rate. The consensus among analysts is a Strong Buy for Monte Rosa Therapeutics, with an average price target of $18.

    Tip Ranks·
    US
    GLUE
    -1.51%
    Tip Ranks·
    US
    GLUE
    -1.51%

    Monte Rosa Therapeutics (NASDAQ:GLUE) Hits New 12-Month High - Should You Buy?

    Monte Rosa Therapeutics (NASDAQ:GLUE) reached a new 52-week high, trading at $15.40. Analysts have mixed ratings: two Buy, one Hold, and one Sell. The average target price is $16.33. The company reported better-than-expected earnings with $12.77 million revenue. Institutional investors hold 79.96% of the stock. Despite the Hold rating, analysts suggest other stocks as better buys.

    Market Beat·
    US
    GLUE
    -1.51%
    Market Beat·
    US
    GLUE
    -1.51%

    Monte Rosa Therapeutics (NASDAQ:GLUE) Trading Up 10.8% Following Analyst Upgrade

    Monte Rosa Therapeutics (NASDAQ:GLUE) shares surged 10.8% after Wells Fargo raised its price target from $10.00 to $13.00, maintaining an equal weight rating. The stock traded as high as $13.59, with a last trade at $13.64. Despite this, Weiss Ratings reaffirmed a "sell (d+)" rating. Institutional investors hold 79.96% of the stock. The company reported earnings of ($0.33) per share, exceeding estimates, with revenue of $12.77 million for the quarter. Analysts forecast a current year EPS of -1.49.

    Market Beat·
    US
    GLUE
    -1.51%
    Market Beat·
    US
    GLUE
    -1.51%

    Monte Rosa Therapeutics shares are trading higher after the company announced it will present preclinical data on the potential of MRT-8102.

    benzinga_article·
    US
    GLUE
    -1.51%
    benzinga_article·
    US
    GLUE
    -1.51%
    Posts
    View More
    © 2025 Longbridge｜Disclaimer